Loading...
XSHG603718
Market cap626mUSD
Dec 26, Last price  
7.10CNY
1D
0.85%
1Q
4.87%
Jan 2017
-60.16%
IPO
51.39%
Name

Shanghai Hile Bio-Technology Co Ltd

Chart & Performance

D1W1MN
XSHG:603718 chart
P/E
72.73
P/S
18.99
EPS
0.10
Div Yield, %
0.80%
Shrs. gr., 5y
-2.40%
Rev. gr., 5y
-1.11%
Revenues
241m
-19.76%
260,127,200310,842,908318,792,688285,272,025316,577,603343,338,733303,650,205254,565,186277,992,965259,128,542347,289,178299,991,674240,722,981
Net income
63m
-48.30%
107,273,400112,545,779118,789,524101,221,38795,402,61585,536,349113,739,53221,298,2230053,856,680121,607,84962,870,202
CFO
-3m
L
149,608,100122,475,830147,626,205110,218,481201,687,364108,388,16734,920,78318,917,48259,251,287167,682,48943,632,976292,905,014-2,938,209
Dividend
Jul 19, 20240.0287 CNY/sh
Earnings
May 23, 2025

Profile

Shanghai Hile Bio-Technology Co., Ltd. researches, develops, produces, and sells veterinary biological products for livestock and poultry in China. The company offers swine fever live vaccines; trivalent inactivated vaccines for piglets; inactivated vaccine for streptococcus suis; pseudorabies live vaccines; inactivated oil emulsion vaccine of porcine parvovirus disease; pathogenic porcine reproductive and respiratory syndrome live vaccines; transmissible gastroenteritis, porcine epidemic diarrhea, and porcine rotavirus triple live vaccines; porcine reproductive and respiratory syndrome live vaccines; swine transmissible gastroenteritis and swine epidemic diarrhea combined inactivated vaccines; porcine circovirus type 2 inactivated vaccines; and swine Japanese encephalitis live vaccines. It also provides chicken infectious bursal disease live vaccines; inactivated avian infectious rhinitis vaccines; newcastle disease and avian influenza combined inactivated vaccines; newcastle disease, infectious bronchitis, egg drop syndrome, and avian influenza quadruple inactivated vaccines; avian influenza inactivated vaccines; newcastle disease, infectious bronchitis, and avian influenza triple inactivated vaccines; avian infectious bronchitis live vaccines; avian newcastle disease and avian infectious bronchitis combined live vaccines; newcastle disease low virulent live vaccines; Marek's disease turkey herpes virus live vaccines; and fowlpox live vaccines. The company was founded in 1981 and is based in Shanghai, China.
URL
http://www.hile-bio.com
IPO date
May 15, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
240,723
-19.76%
299,992
-13.62%
347,289
34.02%
Cost of revenue
191,530
230,890
272,585
Unusual Expense (Income)
NOPBT
49,193
69,102
74,704
NOPBT Margin
20.44%
23.03%
21.51%
Operating Taxes
6,009
20,526
11,473
Tax Rate
12.21%
29.70%
15.36%
NOPAT
43,185
48,575
63,231
Net income
62,870
-48.30%
121,608
125.80%
53,857
 
Dividends
(36,515)
(2,705)
Dividend yield
0.54%
0.03%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
50,829
26,343
12,008
Long-term debt
829
29,736
5,240
Deferred revenue
64,453
66,265
182,195
Other long-term liabilities
1
1
1
Net debt
(940,651)
(415,799)
(521,383)
Cash flow
Cash from operating activities
(2,938)
292,905
43,633
CAPEX
(7,813)
Cash from investing activities
(171,089)
66,130
41,539
Cash from financing activities
159,992
50,008
FCF
98,029
105,023
270,563
Balance
Cash
353,216
392,709
538,632
Long term investments
639,093
79,170
Excess cash
980,273
456,879
521,267
Stockholders' equity
789,891
1,140,334
1,005,606
Invested Capital
500,182
720,986
650,941
ROIC
7.07%
7.08%
7.24%
ROCE
3.81%
5.86%
6.36%
EV
Common stock shares outstanding
628,702
644,000
644,000
Price
10.71
9.06%
9.82
-35.82%
15.30
21.33%
Market cap
6,733,399
6.47%
6,324,080
-35.82%
9,853,200
21.33%
EV
5,882,020
5,908,281
9,331,817
EBITDA
88,901
116,473
132,269
EV/EBITDA
66.16
50.73
70.55
Interest
5,389
10,311
12,377
Interest/NOPBT
10.95%
14.92%
16.57%